MinervaX ApS

MinervaX is pursuing the development of a novel vaccine candidate against Group B Streptococci (GBS), which is responsible for 50% of life-threatening infections in new-born.

Contact name:

Per Fischer


Ole Maaløes Vej 3, 2200 Copenhagen, Denmark

If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

Copyright 2013 Danskbiotek. All rights reserved.